Status:
COMPLETED
Eligard Observational Registry for Patients With Prostate Cancer
Lead Sponsor:
CMX Research
Collaborating Sponsors:
Sanofi
Conditions:
Cancer of the Prostate
Eligibility:
MALE
18+ years
Brief Summary
The objective of this registry is to collect data on patient demographics, medical history, change in prostate, bone and overall health of the patients receiving androgen ablation treatment using Elig...
Detailed Description
354 patients were enrolled in this study. Only 88 patients completed the study. For those patients completing the three years of data collection, 10% were considered Castrate Resistant and remained o...
Eligibility Criteria
Inclusion
- Patients \> 18 years of age.
- Histologically confirmed diagnosis of locally Advanced or Metastatic Prostate Cancer.
- Patient starting an androgen deprivation therapy with Eligard at 3 or 4 month treatment frequency per standard of care.
- Signed written informed consent.
Exclusion
- Prior ADT (within 6 months).
- Any concurrent condition that would make it undesirable, in the physician's opinion, for the subject to participate in the study or would jeopardize compliance with the protocol.
- Life expectancy less than 2 years.
Key Trial Info
Start Date :
August 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2014
Estimated Enrollment :
354 Patients enrolled
Trial Details
Trial ID
NCT00992251
Start Date
August 1 2009
End Date
March 1 2014
Last Update
December 22 2016
Active Locations (36)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr. George Vrabec
Abbotsford, British Columbia, Canada, V2S 3N5
2
Southern Interior Medical Research Corporation
Kelowna, British Columbia, Canada, V1Y 2H4
3
Dr. Cal Andreou
Surrey, British Columbia, Canada, V3V 1N1
4
Dr. Nazif Omar
Surrey, British Columbia, Canada, V3V 1N1